THE $220-$270 million
writedown of the carrying value of
Sigma Pharmaceuticals’
manufacturing division which is
proposed to be sold to Aspen
Pharmacare (PD yesterday)
reportedly has some shareholders
wondering if the company should
have accepted the initial Aspen bid
of 55c per share for the whole
company.
Today’s Financial Review cites
some investors saying they expect a
40c per share capital return, which
may be difficult given the scope of
the proposed writedown.
The story also says that Pulse
Pharmacy, one of Sigma’s biggest
customers, is “coming under
growing financial and operational
pressure from its major lender,
National Australia Bank”.The above article was sent to subscribers in Pharmacy Daily's issue from 17 Sep 10 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 17 Sep 10
THE stark health inequalities between Australians living in regional and metro areas have been highlighted in a new report from The Royal Flying Doctor Service (RFDS).
AN “AI explosion” is sweeping Australia’s healthcare sector, signalling the arrival of an “extraordinary era of medicine”, according to a new report from CSIRO.
THE Australian and New Zealand College of Advanced Pharmacy (ANZCAP) has celebrated the 1,000th pharmacist to complete its pharmacy recognition program (PD 24 Nov 2023).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.